当前位置: 首页 > 期刊 > 《中西医结合心血管病》 > 201816
编号:13580892
心脏x综合征患者临床特征及治疗效果的病例报告(2)
http://www.100md.com 2018年6月5日 《中西医结合心血管病电子杂志》 201816
     [4]Dollard J, Kearney P, Clarke G, et al. A prospective study of C-reactive protein as a state marker in Cardiac Syndrome X[J].Brain, Behavior, and Immunity,2015,43:27-32.

    [5]Ping Q, Luo SH, Guo YL,et al.Evaluation of Red Blood Cell Distribution Width in Patients with Cardiac Syndrome X[J].DISEASE MARKERS,2013,34(5):333.

    [6]Masoudkabir F,Vasheghani-Farahani A, Hakki E, et al. Novel Scoring System for Prediction of Cardiac Syndrome X in Women with Typical Angina and a Positive Exercise Tolerance Test[J].TEXAS HEART INSTITUTE JOURNAL,2018,45(1):5-10.

    [7]Ong P, Athanasiadis A,Sechtem U. Treatment of Angina Pectoris Associated with Coronary Microvascular Dysfunction[J].CARDIOVASCULAR DRUGS AND THERAPY,2016,30(4):351-356.

    [8]Majidiniaa M, Rasmia Y,Ansaria MHK,et al. Metoprolol Improves Endothelial Function in Patients with Cardiac Syndrome X[J].Iranian Journal of Pharmaceutical Research Ijpr,2016,15(3):561-566.

    [9]Kayaalt? F,Kalay N,Basar E, et al. Effects of nebivolol therapy on endothelial functions in cardiac syndrome X[J].HEART AND VESSELS,2010,25(2):92-96.

    [10]Andishmand A,Ansari Z,Soltani MH, et al. Vitamin D replacement therapy in patients with cardiac syndrome X[J].Perfusion,2014,30(1):60-63.

    [11]李 磊,刘建勋,任建勋,等.冠状动脉微循环功能障碍动物模型及中医药防治研究進展[J]. 中国中药杂志,2017,(02):254-258.

    本文编辑:吴宏艳, 百拇医药(苏停停 张勇 王怀根 王东琦)
上一页1 2